Tags

Type your tag names separated by a space and hit enter

Endocannabinoid system and cardiometabolic risk.
Clin Pharmacol Ther. 2007 Nov; 82(5):591-4.CP

Abstract

The increasing prevalence of overweight and obesity counteracts the favorable advances of risk factor management achieved for cardiovascular disease (CVD) prevention. Obese and overweight individuals are at increased risk for CVDs and diabetes mellitus, a risk pattern called "cardiometabolic risk." There is a growing interest concerning the role of the endocannabinoid system in energy metabolism and how blockade of cannabinoid receptors (CB(1)) may optimize fat distribution, insulin sensitivity, and blood lipids to improve cardiovascular risk profile.

Authors+Show Affiliations

General Cardiology & Coronary Care Unit Services, CCR ASCARDIO, Barquisimeto, Venezuela. leonardosaavedra@intercable.net.ve

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17898706

Citation

Saavedra, L E.. "Endocannabinoid System and Cardiometabolic Risk." Clinical Pharmacology and Therapeutics, vol. 82, no. 5, 2007, pp. 591-4.
Saavedra LE. Endocannabinoid system and cardiometabolic risk. Clin Pharmacol Ther. 2007;82(5):591-4.
Saavedra, L. E. (2007). Endocannabinoid system and cardiometabolic risk. Clinical Pharmacology and Therapeutics, 82(5), 591-4.
Saavedra LE. Endocannabinoid System and Cardiometabolic Risk. Clin Pharmacol Ther. 2007;82(5):591-4. PubMed PMID: 17898706.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoid system and cardiometabolic risk. A1 - Saavedra,L E, Y1 - 2007/09/26/ PY - 2007/9/28/pubmed PY - 2007/12/6/medline PY - 2007/9/28/entrez SP - 591 EP - 4 JF - Clinical pharmacology and therapeutics JO - Clin Pharmacol Ther VL - 82 IS - 5 N2 - The increasing prevalence of overweight and obesity counteracts the favorable advances of risk factor management achieved for cardiovascular disease (CVD) prevention. Obese and overweight individuals are at increased risk for CVDs and diabetes mellitus, a risk pattern called "cardiometabolic risk." There is a growing interest concerning the role of the endocannabinoid system in energy metabolism and how blockade of cannabinoid receptors (CB(1)) may optimize fat distribution, insulin sensitivity, and blood lipids to improve cardiovascular risk profile. SN - 1532-6535 UR - https://www.unboundmedicine.com/medline/citation/17898706/Endocannabinoid_system_and_cardiometabolic_risk_ L2 - https://doi.org/10.1038/sj.clpt.6100373 DB - PRIME DP - Unbound Medicine ER -